Remco Molenaar, MD, PhD: TET2 Mutations Predict Cardiovascular Risk in MDS and CMML

Patients with myelodysplastic syndromes and chronic myelomonocytic leukemia and TET2 mutations have high risks of cardiovascular toxicity, suggesting that these patients might benefit from a cardiac work-up at diagnosis. Dr. Molenaar shares results from this SEER analysis.

[@chris7707s]

I have cmml with a pdgfrb ive been on gleevec for 13 yrs